- All 37 sources read in full, not keyword-matched
- Every benefit graded by how far the research has come
- Corrections published openly — including our own
Reader-supported: Advanced MycoTech may earn a commission from some links on this page, at no extra cost to you. It never changes what we recommend, and it never changes how we grade the evidence. Full affiliate disclosure.
The short answer
Of all the functional mushrooms, lion’s mane has the most human evidence behind it — and the most interesting science still ahead of it.
That is a genuinely good position to be in. Lion’s mane (Hericium erinaceus) is the only functional mushroom with multiple randomised human trials pointing the same direction on cognition, it has an excellent safety record across studies running up to a year, and in 2023 researchers identified compounds in it that make neurons grow new branches through a pathway nobody had described before.
It is also a mushroom people have eaten for centuries, which is a longer safety trial than any laboratory will ever run.
What we won’t do is pretend the research is finished. Of the 11 benefits on this page, two have been tested in people — cognition and mood. The other nine are supported by animal and laboratory work: real science, at an earlier stage, of the kind that every approved medicine passes through on its way to human trials. We’ll show you exactly where each one stands.
Our position: lion’s mane is one of the few supplements in this category we think is genuinely worth your money — particularly if you’re in your fifties or beyond and noticing the difference. Take it consistently, give it a couple of months, and treat the rest of this list as reasons to be curious about what the next decade of research turns up.
This article was first published in 2019, and the science has moved a long way since — three new human trials, a major discovery about how lion’s mane works, and a systematic review. Rather than bolt the new material on, we rebuilt the page and re-read all 22 of the original sources against the papers themselves.
Five of them turned out to be described inaccurately. We’ve listed those below, in public, with the source quoted. We think lion’s mane is genuinely worth taking, and the case for it is strong enough that it doesn’t need help from numbers that aren’t there.
What we got wrong before
Five details we described inaccurately. If you read this page between 2019 and July 2026, you saw at least one of them, so here they are with the source quoted beside each.
- Was “Cognitive function continued to improve for the group receiving lion’s mane throughout the duration of trial, and up to 4 weeks after termination of intake.”Actually The opposite. Mori’s 2009 trial reports that “at week 4 after the termination of the 16 weeks intake, the scores decreased significantly” [1]. The benefit did not persist — it was lost on stopping. This is the single most important finding on the page, and we had it backwards.
- Was “Half the group received 250 mg tablets of 96% dry lion’s mane powder three times a day.”Actually Four 250 mg tablets, three times a day — 3,000 mg daily, not 750 mg [1]. A fourfold understatement, and it matters to anyone trying to match the clinical dose with a product. See the dose nobody mentions.
- Was “Studies performed in normal and diabetic mice showed that even low doses of lion’s mane mushroom (6 mg per kg of body weight) significantly lowered blood glucose levels.”Actually Wistar rats, not mice, and 100–200 mg/kg, not 6 [14]. The string “6 mg” does not appear in the paper. The dose was overstated as low by a factor of roughly 20.
- Was “A 44% reduction in stroke-related brain injury when rats were given a high dose of lion’s mane mushroom extract immediately after a stroke.”Actually The 44% is real, but the timing is reversed. Erinacine A was given “during the 5 days before the onset of ischemia” [18]. It is a prevention study in rats, not an emergency treatment. (The paper’s own abstract contradicts its methods section on this point, which is likely how the error started.)
- Was “Rats with injuries to the nervous system had up to a 41% reduction in recovery time.”Actually There is no 41% in that paper [17]. It reports recovery “4–7 days earlier” than untreated controls, with no difference between low and high doses. The only 41 in the study is a score belonging to the comparison drug, mecobalamin — not to lion’s mane.
The 2019 version leaned on one human study and nineteen animal, laboratory and background sources — and presented them all with roughly equal confidence. That’s the norm in this category, and it’s the thing that makes people distrust supplements generally.
Lion’s mane doesn’t need that treatment. It now has eight randomised human trials to its name, more than any other functional mushroom, plus a safety record most supplements would envy. The rest of this page sorts the strong evidence from the early evidence, so you can see the real case — which we think is a good one.
How we graded
Every benefit below carries one of four labels showing how far the research has travelled. Science moves in stages — a compound is studied in a dish, then in animals, then in people — and lion’s mane is at a different point on that road for each claim. The label tells you where.
| Grade | What it means |
|---|---|
| Clinical evidence | Randomised, placebo-controlled trials in people have measured this and found an effect. The strongest tier any supplement claim can reach. |
| Early clinical | Human trials exist and point in a promising direction, but they are small or early. Encouraging, not yet settled. |
| Preclinical | Demonstrated in animals. This is the stage every approved medicine passes through on its way to human trials — real evidence, one step short of proof in people. |
| Laboratory | Shown in cells or a chemical assay. The earliest signal there is, and where a lot of good science starts. |
Preclinical results matter — they are how every drug in your medicine cabinet got started, and they are why researchers are pointing serious money at this mushroom. They are also an imperfect predictor: in oncology, where this has been measured most carefully, fewer than 8% of animal findings carry through to a successful human trial [19].
So we treat them as what they are — genuine reasons for interest, and not yet reasons to promise you a result. When we say a benefit is preclinical, read it as “watch this space,” not “forget it.”
The evidence scorecard
All 11 benefits and where the research has reached on each one. Two are backed by human trials; the rest are at the animal or laboratory stage, which is where most of the exciting work in this field currently sits.
| Claimed benefit | Grade | Where the research stands |
|---|---|---|
| Cognition | Clinical evidence | Eight randomised trials, most pointing the same way in older adults. Small studies, and the landmark result is still awaiting replication. |
| Depression, anxiety and mood | Early clinical | Three human trials, all finding improvement in mood or sleep. Each is small, and we name the limitations of each. |
| Nerve growth factor (NGF) | Preclinical | Strong signal in cells and mice — this is the mechanism the whole category is built on. Human measurement is still to come. |
| Nerve injury recovery | Preclinical | Injured rat nerves recovered 4–7 days faster. Consistent across studies; the clinical trials haven’t been run yet. |
| Chronic inflammation | Preclinical | Reproducible anti-inflammatory effects in mice. No human trial has measured inflammatory markers yet. |
| Blood sugar / diabetes | Preclinical | Clear blood-sugar effects in diabetic rats. Glucose was unchanged in the one human trial that looked. |
| Heart disease risk | Preclinical | Improved fat metabolism in rats, though that study has a confound worth knowing about. |
| Cancer | Preclinical | Encouraging results against human tumor cells in mice. A long way from anything you could call a treatment. |
| Immune function | Preclinical | Immune benefits in mice via the gut microbiome, using a purified compound rather than a supplement. |
| Oxidized LDL cholesterol | Laboratory | Promising test-tube chemistry, including the enzyme statins target. Human cholesterol data doesn’t yet support it. |
| Stomach ulcers / H. pylori | Laboratory | Inhibits the ulcer bacterium H. pylori in the lab. Human testing has essentially not begun. |
The 11 benefits, one by one
1. Cognition
Clinical evidenceThis is the claim that built the category, and it deserves to have: it has more human evidence behind it than any other functional mushroom claim in existence. Here is that evidence, including the parts that are still unresolved.
The founding trial. Thirty Japanese adults aged 50–80 with mild cognitive impairment took 3,000 mg a day of dried fruiting-body powder for 16 weeks [1]. Their scores climbed steadily at weeks 8, 12 and 16 — a real, measurable improvement in exactly the group you would hope to help. Four weeks after they stopped, the scores fell back again, which tells you something useful: this works while you take it.
Two honest caveats. The authors worked for a mushroom company, and the placebo group improved somewhat too, so practice effects can’t be ruled out. And in seventeen years nobody has run the same trial again — a 2024 review by a panel of neurologists notes the finding “has yet to be replicated” [35]. That is a gap in the literature, not a mark against the mushroom.
The trial in healthy older adults. A 12-week randomised trial gave 3.2 g/day of fruiting-body powder to healthy adults over 50, and the treatment group’s cognitive scores improved significantly [2]. Worth reading closely though: they started at 29.19 out of 30 and finished at a perfect 30.00, so there was very little room to move, and two other tests in the same study showed no change. A win, but a modest one.
The longest trial, in Alzheimer’s. Forty-nine weeks in people with mild Alzheimer’s, using an erinacine A-standardized mycelium [20]. The headline result was on independent daily living — the treated group held onto everyday function significantly better than placebo, which for a family living with early Alzheimer’s is arguably the outcome that matters most. Contrast sensitivity also improved.
Be careful how this one gets quoted, though. On the cognitive scales themselves — MMSE, CASI and the Neuropsychiatric Inventory — there was no significant difference between groups. The MMSE number often cited is a within-group change, and six of the ten authors worked for the manufacturer. It is a real signal on function, not proof of a cognitive effect.
Two recent trials found lion’s mane performing worse than placebo on specific measures. We’d rather you heard it from us.
In the 28-day trial in healthy young adults, participants recalled fewer words after a dose acutely, and at day 29 the placebo group significantly out-recalled them on delayed recall [3]. In a 2025 single-dose crossover, the primary outcomes were null and two measures were significantly worse on lion’s mane — Flanker task performance and Trail Making B — with those negatives surviving correction for multiple comparisons [29].
And the highest dose ever tested in a human — 10 g a day for four weeks — showed no cognitive effect at all [22]. A useful data point in its own right: more is not better here.
What the reviews conclude. A 2025 systematic review found a combined weighted gain of 1.17 points on the 30-point MMSE and concluded lion’s mane “shows limited effectiveness in clinical trials” [4]. It could not run a meta-analysis because the underlying studies report too incompletely. There is no meta-analysis of lion’s mane and cognition. There is no Cochrane review. The Alzheimer’s Drug Discovery Foundation’s independent assessment, updated July 2025, is that effects “have been mixed based on a few small pilot clinical trials.”
Our reading: a real, repeatable signal in the people most likely to benefit — older adults noticing decline — of modest size, dependent on staying consistent. That is a more honest and more useful promise than “boosts your brain,” and it is more than any other functional mushroom can claim. That still makes lion’s mane the strongest candidate on our mushroom supplements for brain health shelf — the competition is weaker, not stronger. See also does lion’s mane actually work and how long it takes.
2. Depression, anxiety and mood
Early clinicalThree human trials, and all three moved in the right direction. Each has a limitation worth knowing, so here they are with the caveats attached.
Thirty women, four weeks, cookies [5]. Depression scores fell — but as a within-group change against baseline, not against the placebo arm. Only two narrow sub-scores beat placebo outright. One thing to know, since this trial gets cited a lot for menopause and sleep: neither of those measures actually moved. The mood result is the real finding here, and it’s the one worth carrying forward.
Seventy-seven people with overweight or obesity, eight weeks [6]. Depression, anxiety and sleep scores all improved. There was no placebo and no blinding — the control group simply got the diet. Everyone was on a low-calorie diet throughout, which lifts mood independently. For subjective questionnaires in an unblinded trial, this is close to uninterpretable.
Forty-one young adults, 28 days [3]. Subjective stress trended lower at p = 0.051 — not significant — and the validated Perceived Stress Scale showed nothing.
Three studies, three improvements, three imperfect designs. That combination is genuinely encouraging and genuinely unproven — the next well-powered trial could settle it either way. More in lion’s mane for anxiety and for depression.
3. Nerve growth factor
PreclinicalNerve growth factor is the mechanism most of the lion’s mane world is built on, and it’s genuinely fascinating chemistry. It is also the claim where the gap between the marketing and the human evidence is widest, so it’s worth walking through carefully.
The foundational work is from the 1990s: extracts of lion’s mane raise NGF secretion in cultured glial cells. Not neurons — glia. And the story got more complicated in 2008, when a follow-up study found that hericenones C, D and E failed to promote NGF gene expression in human astrocytoma cells [9]. That paper concluded lion’s mane does contain NGF-stimulating compounds — but that they are not the hericenones everyone names.
Almost no human trial has ever measured NGF. Of the dozen human studies of lion’s mane, exactly one included it: an 8-month trial in elderly hearing-impaired patients [36]. Its NGF difference appeared only in an over-65 subgroup rather than the whole sample, the paper is not indexed in PubMed, and several authors work for the company that made the product. That is the entire human NGF evidence base.
The trials that measured a neurotrophin measured BDNF, and the answers are inconsistent. One found the precursor pro-BDNF rose while mature BDNF did not move at all [6] — and pro-BDNF is associated with the opposite of what you would want. In the 49-week Alzheimer’s trial, the between-group BDNF difference came from the placebo group declining, not the treatment group rising [20].
None of this means lion’s mane doesn’t act on the nervous system — the 2023 work below makes a strong case that it does, by a different and arguably more interesting route. It means the specific phrase “boosts NGF” has outrun its evidence, and the real mechanism story is newer and better than the one on the label.
4. Nerve injury recovery
PreclinicalRats with surgically crushed nerves regained function 4–7 days earlier than untreated controls, with no difference between low and high doses [17]. This is the study our 2019 version turned into “up to a 41% reduction in recovery time,” a number that does not appear in it.
Separately, rats given erinacine A for five days before an induced stroke had 44% smaller brain lesions [18] — a striking protective effect, as prevention in a rodent rather than rescue in a person. A 2026 systematic review found eleven studies here, all preclinical, and called for clinical trials. This is one of the most active research fronts for the mushroom. See lion’s mane for nerve repair.
5. Chronic inflammation
PreclinicalReasonable rodent evidence that lion’s mane extracts dampen inflammatory signalling. No human trial has measured an inflammatory marker as a lion’s-mane-attributable outcome.
Worth flagging: the paper this article originally cited for “immune-stimulating, antioxidant and anti-inflammatory properties” [10] ran only antioxidant assays. No immune assay, no inflammation assay. Two of the three properties were lifted from a background sentence about oligosaccharides as a general class.
6. Blood sugar and diabetes
PreclinicalDiabetic rats given 100–200 mg/kg for 28 days showed clearly lower blood glucose [14] — a solid animal result, though scaled by body weight it is a substantial dose, not the “low dose” our old version described.
In the one human trial to measure fasting glucose, it was unchanged [30], so don’t take lion’s mane expecting blood-sugar help yet. If you’re on diabetes medication, mention it to your doctor anyway — the animal data is strong enough to be worth flagging.
7. Heart disease risk
PreclinicalOne 2-week study in obese rats, eight animals per group, found lower triglycerides [13]. The confound is unusual: the mushrooms were grown on Artemisia capillaris (mugwort), and the study confirmed mugwort extract alone also lowers lipids.
There is as yet no human cardiovascular data of any kind for lion’s mane. If heart health is your main goal, this is not the mushroom the evidence points to — and we would rather send you to the right one than sell you this one.
8. Cancer
PreclinicalThe strongest study implanted human gastrointestinal tumors into immune-deficient mice and reported lion’s mane extracts outperforming 5-fluorouracil [15]. Our 2019 version rendered that as “more effective than traditional cancer medications.” What that hides:
- “Traditional cancer medications” means one drug, 5-FU.
- The comparison is not like-for-like: extracts given orally and daily at 500–1,000 mg/kg, against 5-FU injected at maximum tolerated dose for five days only.
- The model is a xenograft in a mouse with no immune system — the setting where translation to humans fails most often.
The authors themselves call the result unexplained and their combination data preliminary. It is a genuinely interesting finding and a reason for researchers to keep looking. To be completely clear: lion’s mane is not a cancer treatment, and nobody should use it as one or delay real care because of it.
9. Immune function
PreclinicalMice given a lion’s mane preparation showed immune changes mediated through the gut microbiota [16]. The agent was HEP3, a purified fungal protein isolated in a laboratory — not the hot-water extract in a capsule.
The gut-immune route is a plausible and increasingly well-studied mechanism — it simply hasn’t reached human trials yet; a 2025 review looking for them found none to include. (One tidy-up while we’re here: the “100 trillion gut cells outnumbering your own 10 to 1” figure this article used to quote was revised in 2016 to roughly 1:1.)
10. Oxidized LDL cholesterol
LaboratoryLion’s mane extract inhibited LDL oxidation in a test tube and inhibited HMG-CoA reductase, the enzyme statins target [11]. That is the whole finding — no animal, no person.
The one piece of human data doesn’t support it, though. In a 2024 randomised pilot in adults aged 55–75, LDL rose slightly and HDL fell in the lion’s mane group [30]. The difference wasn’t statistically significant, so this is not evidence of harm — but it is the only human cholesterol data there is, and it doesn’t point the way the marketing does. We’d rather tell you than skip it.
11. Stomach ulcers and H. pylori
LaboratoryLion’s mane extracts inhibited Helicobacter pylori on a culture plate [12]. To its credit, the 2019 version of this article labelled this one honestly as in vitro, and it remains in vitro.
The only human publication on lion’s mane and gastritis is a two-page preliminary report from 1985 whose methods can’t be retrieved, so we can’t verify it. Promising laboratory chemistry, essentially untested in people — a good candidate for someone’s next trial.
How lion’s mane actually works
This is the part we find genuinely exciting. Lion’s mane makes three families of compounds found almost nowhere else in nature, and where each one lives inside the fungus turns out to decide what you should buy.
- Hericenones — 24 known, found in the fruiting body, the white pom-pom you would recognise as the mushroom [8].
- Erinacines — 23 known, produced predominantly in the mycelium, the root-like growth phase. A 2025 study measuring the biosynthetic genes directly found no detectable erinacines in fruiting-body tissue at all [31]. Notably, it came from the research department of a company that sells mycelium products — a finding published against its own commercial interest, which is why we trust it.
- Hericerin derivatives — including hericene A and NDPIH. This is a third class, and it is where the most interesting recent work landed.
In 2023 a University of Queensland team watched hericene A and NDPIH make hippocampal neurons sprout dramatically longer axons with far more branching — you can see it down a microscope — and found that mice fed hericene A had measurably better memory [7]. The pathway is ERK1/2, and it was not on anyone’s map before this.
That is the kind of result that makes researchers pay attention to a mushroom. It is still neurons in a dish and memory in a mouse — but it is a real mechanism, freshly discovered, in a food people have eaten for centuries.
Worth knowing for what you buy: that work was done on fruiting bodies. The compounds were purified from an ethanol extract of dried fruiting body — no mycelium was involved anywhere in the study. The most-cited recent mechanism paper in lion’s mane neuroscience is a fruiting-body paper.
“Hericenones and erinacines cross the blood-brain barrier” appears on nearly every lion’s mane page, including earlier versions of ours. It has never been shown for hericenones. The pharmacokinetic studies everyone cites for it measured erinacines — in rats. We traced three separate reviews making the claim and citing a paper that only tested erinacine S. A 2025 narrative review argues the opposite: that hericenones have failed both to raise NGF in the relevant cell line and to cross the barrier [37].
The accurate statement is that nobody has measured it, in either direction.
You will read everywhere that lion’s mane “activates the BDNF–TrkB pathway.” That paper found the opposite. NDPIH activated ERK1/2 in cells that lack TrkB entirely, and blocking TrkB only partly prevented the effect. The authors’ own conclusion is that it works through a pathway independent of TrkB that converges downstream. It is a pan-neurotrophic, TrkB-independent mechanism — which is more interesting than the version in the marketing, and different from it.
Getting the dose right
Two things sit between the research and the bottle on your shelf. Knowing about them puts you ahead of most people buying this.
First, how much actually reaches the brain. Erinacine A does cross the blood-brain barrier in rats, with oral bioavailability around 24% [34] — encouraging, and the basis for the whole neuro story. What’s missing is the human version: no study has yet measured any lion’s mane compound in a person’s bloodstream, let alone their brain.
The scale is worth knowing. The rat studies used 50 mg/kg of erinacine A; adjusted for body size that’s several hundred milligrams for a person, while human trials have used about 5 mg a day. That comparison is crude — detection in a rat brain isn’t the same as the threshold for an effect — but it suggests the products we have may be at the low end of what’s possible, and that better ones are likely coming.
Second, the clinical dose and the label dose measure different things. The trials that found cognitive effects used 2 to 3.2 g a day of plain dried powder, while a typical capsule gives you around 1,000 mg of concentrated extract. An extract carries more raw mushroom than its own weight — but how much more depends on an extraction ratio most brands don’t publish, and “10:1” on a label describes a mass ratio, not what actually concentrated. So don’t assume a smaller number means a smaller dose.
Ignore milligrams of “mushroom” and look for beta-glucan percentage, measured by an assay that separates beta-glucan from alpha-glucan. A “polysaccharides” number is close to useless, because the traditional method counts starch as polysaccharide — so on a grain-grown product it can be substantially measuring the grain. Our guide to beta-glucans and how to read a COA cover the detail; the dosage guide works through the conversion.
How to choose a good one
One fact explains most of the confusion in this aisle: no two lion’s mane trials have ever tested the same product. Plain dried powder, cookies, an 80/20 mycelium blend, a fermented erinacine-standardized mycelium, an unspecified “mushroom complex,” a 10:1 extract. Every clinical result belongs to its own preparation, and none of them is the thing on your shelf.
Fruiting body or mycelium? The usual answer — fruiting body, always — is too simple, and getting it right is worth doing. There are three categories, not two:
- Fruiting body. Hericenones and hericerins, verifiable beta-glucans, near-zero alpha-glucan. What the positive powder trials used.
- Liquid-fermented mycelium, harvested from the broth with no grain involved. This is what the 49-week Alzheimer’s trial used, standardized to a measured erinacine A content. It is a legitimate, clinically studied category — and it is largely unavailable at US retail.
- Mycelium grown on grain and milled together with its substrate. This is the actual target of the criticism, because the rice or oats stays in the product.
So the real point isn’t that mycelium is fake — it’s that fruiting body and mycelium are chemically different supplements with different evidence behind them, and grain-grown mycelium dilutes both. We default to fruiting body because it’s verifiable, available, and what most of the positive human trials used.
The best-known source for “fruiting bodies are 30–40% beta-glucan, mycelium-on-grain products are 35–40% starch” is a 2015 industry white paper by Jeff Chilton of Nammex. It is not peer reviewed, its lion’s mane sample size was one, and the comparison extracts were the author’s own product.
It also matters here specifically: Jeff Chilton co-founded Real Mushrooms — the brand we recommend below and earn commission on — with his son Skye, and Nammex supplies it. We are relying on a fruiting-body argument whose most-cited source is the supplier of the product we make money from. You should know that.
The direction of the argument does hold up in independent work: a 2017 US Pharmacopeial-affiliated study found only 5 of 19 retail reishi supplements matched their labels. But the specific lion’s mane percentages are not independently established. The one peer-reviewed measurement of lion’s mane fruiting body puts beta-glucan at 17.4%, not 37% [32] — and that same study confirms fruiting body is naturally 0.67% alpha-glucan, which makes alpha-glucan an unusually clean test for grain contamination in this species.
The variation nobody argues about is the biggest one. A 2026 analysis of commercial products found hericenone C ranging from 0.005 to 0.503 mg/g across fruiting-body products — a hundredfold spread within the category everyone agrees is the good one [33]. “Fruiting body” on a label predicts far less than the debate implies. That method is new, and a brand that can show you those numbers is ahead of the field.
Is it extracted? Raw powdered mushroom is largely indigestible chitin; hot water is what makes beta-glucans available. And for lion’s mane specifically, dual extraction is chemically justified rather than marketing — hericenones are lipophilic and are isolated in the laboratory from a hexane fraction, so water alone will not pull them out. The caveat: no product standardizes to hericenones, and no human trial has ever tested one that did.
Seventeen lion’s mane trials are registered on ClinicalTrials.gov — including a 24-month Parkinson’s study in 80 people, and trials of 144, 120 and 105 participants. That’s roughly 700 people’s worth of data in the pipeline, several times everything published to date.
None of it has been released yet, which is worth knowing when anyone tells you the science is settled in either direction. Unpublished results do tend to skew negative, so we’re holding our expectations loosely — but this is a field about to get a lot more evidence, and we’ll update this page as it lands.
The two we use
Both are Real Mushrooms, and both are the same thing in different packaging: hot-water extract of lion’s mane fruiting bodies, 1,000 mg per serving, third-party tested, with a stated beta-glucan floor. Pick on format, not potency.
Lion’s Mane Extract Capsules
120 capsules, 60 servings at 1,000 mg. The format that actually gets taken daily, which matters more than any spec on this page — the cognitive trial that found an effect needed 16 straight weeks.
Check price at Real Mushrooms →20% OFFGifted through our link — tap “Redeem Offer” and it auto-applies at checkout.
Lion’s Mane Extract Powder
60 g, also 60 servings at 1,000 mg. Lets you scale up or down without counting capsules, and it disappears into coffee. Mildly bitter on its own.
Check price at Real Mushrooms →20% OFFGifted through our link — tap “Redeem Offer” and it auto-applies at checkout.
We tested more than these two
Real Mushrooms is what we take, but it is not the only defensible option, and it is not the cheapest per gram. The full ranking covers the brands worth considering and the ones that quietly sell you grain.
See the best lion’s mane supplements of 2026 →How safe is it?
This is one of lion’s mane’s real strengths, and it’s the reason we’re comfortable recommending it at all.
The US National Institutes of Health’s LiverTox database maintains a dedicated lion’s mane monograph and assigns it a Likelihood Score of E — “unlikely cause of clinically apparent liver injury”, its lowest-risk category [26]. Health Canada lists it as a permitted ingredient whose only mandated caution is to consult a practitioner if pregnant or breastfeeding — the lightest risk profile of any mushroom in that monograph, lighter than reishi, shiitake or maitake [28].
People have also been eating this mushroom for centuries. That’s not clinical evidence, but it isn’t nothing either. Here’s the detail behind those verdicts, including the limits of what has actually been checked.
Roughly 220 people have ever taken lion’s mane inside a controlled human trial. Of those, about 28 have had blood drawn afterwards to check liver or kidney chemistry — fifteen in one 16-week trial and thirteen in an uncontrolled 7-day study [1][23].
Several trials collected safety data and never published it. A 77-person trial administered a safety questionnaire and reported no result from it, while all eight of its dropouts came from the lion’s mane arm and none from the control arm, with no reasons given [6]. The 28-day young-adult trial states in its methods that participants reported adverse outcomes, then never mentions them again [3].
And when you read that “trials have used up to 10 grams safely,” the study being referred to [22] collected no safety data at all — no questionnaire, no blood work. Nobody came to harm in it, but it can’t support the claim it gets used for. At ordinary doses the record is genuinely reassuring; it’s the very high doses that are simply unstudied.
What was found where anyone looked
Where adverse events were properly tracked, the picture is calm. A 40-person crossover study that pre-specified adverse-event monitoring recorded zero events in the lion’s mane arm [21].
Digestive upset is the main thing to expect, and it’s about as common on placebo. In the 16-week cognition trial, 7 of 15 people on lion’s mane (47%) reported mild stomach discomfort or diarrhea — against 6 of 15 on placebo (40%) [1]. One person in the lion’s mane arm withdrew citing stomach discomfort. That is the most honest summary available: GI symptoms happen often, and the trials cannot distinguish them from what happens anyway.
The longest trial found a small but real discontinuation signal. A 49-week study in mild Alzheimer’s disease — the only lion’s mane trial ever run with FDA-style adverse-event monitoring and an independent safety committee — had three participants discontinue for side effects in the active arm against one on placebo, reporting abdominal discomfort, nausea and skin rash [20]. Skin rash appeared only in the active arm. The same paper openly concedes that it did not collect long-term liver, kidney or urinalysis data.
Blood chemistry, where measured, has been unremarkable or favorable. Liver enzymes did not move meaningfully in either trial that checked them. A 7-day study found creatinine and uric acid decreased, which is the opposite of a kidney-stress pattern, and the 16-week trial saw creatinine fall in the lion’s mane arm too [1][23]. Two small studies agreeing in direction is the most defensible cross-trial signal in this literature, and it is a reassuring one.
In 2003, a 63-year-old Japanese man with untreated diabetes was hospitalised with acute respiratory distress syndrome after taking a lion’s mane extract for four months [24]. A lymphocyte stimulation test showed strong reactivity to the extract, pointing to an allergic mechanism. He recovered on steroids and mechanical ventilation. It remains the only published report of its kind in more than two decades.
This is why the allergy caution is not boilerplate. If you react to mushrooms or molds, do not take lion’s mane.
One further case sometimes gets attached to lion’s mane and should not be: a 2025 report of grade 3 liver injury in a cancer patient taking a mushroom powder blend, where the authors attribute the effect to Agaricus blazei, a co-ingredient, and not to lion’s mane [25].
Interactions, honestly
The 2025 systematic review pooled 26 studies and cataloged every adverse event reported across them. No drug interaction appears anywhere in that record — and interactions were not a topic the review set out to examine [4]. The warnings you will read elsewhere — blood thinners, diabetes medication — are precautionary inferences drawn from rodent and laboratory work, not events observed in people.
That is a reason to tell your doctor you are taking it, not a reason to be alarmed. Do mention it if you are on anticoagulants, managing blood sugar with medication, or scheduled for surgery. Our side effects guide takes each one apart.
Pregnancy and breastfeeding: there is no data at all. Not reassuring data — none. Absence of evidence here means avoid.
The FDA’s consumer complaint system contains several dozen reports mentioning lion’s mane. Those reports are self-submitted, uninvestigated, and carry no causality assessment — the agency says so itself. They cannot show that a product caused anything, and quoting the alarming ones while ignoring that limitation is how supplement scare stories get written. We have read them. They do not change the picture above, and we do not think they belong in an evidence article.
FAQ
What is lion’s mane actually proven to do?
Support cognition in older adults, measurably, while you keep taking it — that’s the benefit with the most human evidence behind it, and no other functional mushroom can say the same. A 2025 systematic review put the pooled improvement at about 1.17 points on the 30-point Mini-Mental State Examination: a modest, real effect rather than a dramatic one. There is also encouraging early human evidence for mood and sleep.
How long does lion’s mane take to work?
The trials that found cognitive effects ran 12 to 49 weeks, with improvement showing from around week 8. A single dose has been shown to speed up one reaction-time task within an hour, though the same study found weaker word recall at that moment — so don’t judge it on day one. Give it two to three months, taken consistently.
Do the benefits last after you stop taking it?
They fade. Four weeks after participants finished a 16-week course, their scores had dropped back significantly. Think of lion’s mane the way you’d think about exercise or good sleep — something you keep doing rather than a course you complete. Plan it as an ongoing habit and the evidence is on your side.
Does lion’s mane work if I am young and healthy?
Honestly, probably not in a way you would notice. The trial in healthy young adults, average age 26, found no change in overall cognitive performance after 28 days. Every positive trial recruited people with age-related decline or mild impairment, which makes sense — that’s where there’s room to improve. If you’re young and sharp there’s no harm in it, but we’d rather you spent the money when you’d actually feel the benefit.
What dose should I take?
The cognitive trials used 2 to 3.2 g daily of dried powder; most capsules supply around 1,000 mg of concentrated extract, which measures a different thing. Health Canada caps dried powder at 2.8 g a day and aqueous extracts at 12 g. Since few brands publish an extraction ratio, comparing beta-glucan percentages tells you more than comparing milligrams. Our dosage guide works it through.
Is lion’s mane better as fruiting body or mycelium?
Fruiting body, for most buyers — it carries the hericenones, lets you verify beta-glucan content, and avoids the grain problem. Worth knowing that the 49-week Alzheimer’s trial used an erinacine A-enriched mycelium, so the longest human data sits on a mycelium product. That is a very different thing from the grain-grown mycelium powder in most US supplements, and both can be good — see our full comparison.
Can lion’s mane treat Alzheimer’s, cancer or diabetes?
No, and please don’t use it as one or delay real treatment. The 49-week Alzheimer’s pilot did show better preservation of everyday independence, which is genuinely promising and worth following, but it found no difference on the cognitive scales themselves. The cancer work is in mice; the blood-sugar work is in rats. No supplement may legally be sold to treat a disease, and the FDA has issued warning letters to lion’s mane sellers who implied otherwise. Think of it as support for healthy ageing, not as medicine.
Is lion’s mane safe to take every day?
For most people, yes — and daily is how it’s meant to be taken. Trials have run up to 49 weeks, the NIH’s LiverTox database rates it unlikely to cause liver injury, and Health Canada’s only required caution concerns pregnancy. Mild digestive upset is the usual complaint, and it shows up at roughly the placebo rate. Skip it if you have a mushroom or mold allergy, and skip it in pregnancy and breastfeeding, where there’s simply no data yet.
Why is lion’s mane restricted in some countries?
Not for safety reasons. In the EU, lion’s mane fruiting body and its aqueous extract are classed as traditional foods, while dehydrated mycelium powder counts as a novel food needing pre-market authorisation, because member states found no record of significant consumption before 1997 [27]. Australia doesn’t list it as a permitted ingredient at all. Neither is a finding of harm — both are about paperwork and product form.
Where we land on it
Lion’s mane is not a miracle, and it was never going to be. What it is: the best-evidenced functional mushroom you can buy, with a safety record most supplements would envy, a genuinely novel mechanism discovered only three years ago, and centuries of people eating it quite happily before any of us thought to measure it.
If you’re in your fifties or beyond and noticing the difference, that combination is worth two or three months of your attention. Take a real dose, take it consistently, and judge it on how you feel rather than on what a label promises. And when the next wave of trials lands, you’ll read about it here — including the parts we’d rather not have to write.
See the lion’s mane supplements we rate →References
Every source below was read in full and checked against the claim it supports. Study type is stated so you can weigh each one yourself.
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367–72. PMID 18844328 — human RCT, n=30. Authors affiliated with Hokuto Corporation.
- Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019;40(4):125–31. PMID 31413233 — human RCT, 12 weeks. MMSE improved; two other tests did not.
- Docherty S, Doughty FL, Smith EF. The acute and chronic effects of lion’s mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study. Nutrients. 2023;15(22):4842. PMID 38004235 — human RCT, n=41, healthy young adults.
- Menon A, Jalal A, Arshad Z, Nawaz FA, Kashyap R. Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Front Nutr. 2025;12:1641246. PMID 40959699 — systematic review of 26 studies including 5 RCTs.
- Nagano M, Shimizu K, Kondo R, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010;31(4):231–7. PMID 20834180 — human trial, n=30 women, 4 weeks.
- Vigna L, Morelli F, Agnelli GM, et al. Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity. Evid Based Complement Alternat Med. 2019;2019:7861297. PMID 31118969 — human trial, n=77, confounded by concurrent low-calorie diet.
- Martínez-Mármol R, Chai Y, Conroy JN, et al. Hericerin derivatives activate a pan-neurotrophic pathway in central hippocampal neurons converging to ERK1/2 signaling enhancing spatial memory. J Neurochem. 2023;165(6):791–808. PMID 36660878 — cell culture + mice.
- Chong PS, Fung ML, Wong KH, Lim LW. Therapeutic potential of Hericium erinaceus for depressive disorder. Int J Mol Sci. 2019;21(1):163. PMID 31881712 — review; source for compound distribution and blood-brain barrier passage.
- Mori K, Obara Y, Hirota M, et al. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull. 2008;31(9):1727–32. PMID 18758067 — in vitro + small mouse arm.
- Hou Y, Ding X, Hou W. Composition and antioxidant activity of water-soluble oligosaccharides from Hericium erinaceus. Mol Med Rep. 2015;11(5):3794–9. PMID 25529054 — in vitro; antioxidant assays only.
- Rahman MA, Abdullah N, Aminudin N. Inhibitory effect on in vitro LDL oxidation and HMG Co-A reductase activity of the liquid-liquid partitioned fractions of Hericium erinaceus. Biomed Res Int. 2014;2014:828149. PMID 24959591 — in vitro.
- Shang X, Tan Q, Liu R, Yu K, Li P, Zhao GP. In vitro anti-Helicobacter pylori effects of medicinal mushroom extracts, with special emphasis on the lion’s mane mushroom, Hericium erinaceus. Int J Med Mushrooms. 2013;15(2):165–74. PMID 23557368 — in vitro.
- Choi WS, Kim YS, Park BS, Kim JE, Lee SE. Hypolipidaemic effect of Hericium erinaceum grown in Artemisia capillaris on obese rats. Mycobiology. 2013;41(2):94–9. PMID 23874132 — rats, 2 weeks, n=8/group; substrate confound.
- Liang B, Guo Z, Xie F, Zhao A. Antihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericium erinaceus in experimental diabetic rats. BMC Complement Altern Med. 2013;13:253. PMID 24090482 — rats, 100–200 mg/kg.
- Li G, Yu K, Li F, et al. Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers. J Ethnopharmacol. 2014;153(2):521–30. PMID 24631140 — xenograft in SCID mice + in vitro.
- Diling C, Xin Y, Chaoqun Z, et al. Immunomodulatory activities of a fungal protein extracted from Hericium erinaceus through regulating the gut microbiota. Front Immunol. 2017;8:666. PMID 28713364 — mice + in vitro; purified protein HEP3.
- Wong KH, Naidu M, David P, et al. Peripheral nerve regeneration following crush injury to rat peroneal nerve by aqueous extract of medicinal mushroom Hericium erinaceus. Evid Based Complement Alternat Med. 2011;2011:580752. PMID 21941586 — rats. Carries a 2018 corrigendum for duplicate publication.
- Lee KF, Chen JH, Teng CC, et al. Protective effects of Hericium erinaceus mycelium and its isolated erinacine A against ischemia-injury-induced neuronal cell death. Int J Mol Sci. 2014;15(9):15073–89. PMID 25167134 — rats, dosed 5 days before ischemia.
- Mak IWY, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114–8. PMID 24489990 — review; source for the animal-to-human translation rate.
- Li IC, Chang HH, Lin CH, et al. Prevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Front Aging Neurosci. 2020;12:155. PMID 32581767 — human RCT, 49 weeks; the longest lion’s mane trial, and the only one with independent safety monitoring.
- La Monica MB, Raub B, Ziegenfuss EN, et al. Acute effects of naturally occurring guayusa tea and Nordic lion’s mane extracts on cognitive performance. Nutrients. 2023;15(24):5018. PMID 38140277 — human crossover, n=40, single 1 g dose; no adverse events in the lion’s mane arm.
- Grozier CD, Alves VA, Killen LG, et al. Four weeks of Hericium erinaceus supplementation does not impact markers of metabolic flexibility or cognition. Int J Exerc Sci. 2022;15(2):1366–80. PMID 36582308 — human trial, n=24, 10 g/day; no safety data collected.
- Xie XQ, Geng Y, Guan Q, et al. Influence of short-term consumption of Hericium erinaceus on serum biochemical markers and the changes of the gut microbiota. Nutrients. 2021;13(3):1008. PMID 33800983 — uncontrolled human pilot, n=13, 7 days.
- Nakatsugawa M, Takahashi H, Takezawa C, et al. Hericium erinaceum (yamabushitake) extract-induced acute respiratory distress syndrome monitored by serum surfactant proteins. Intern Med. 2003;42(12):1219–22. PMID 14714963 — case report.
- Strobbe G, Bonneau A, Gomez-Mascard A, et al. Grade 3 cytolysis in a patient with metastatic colorectal cancer consuming a mushroom powder-based supplement. J Oncol Pharm Pract. 2025;31(2):329–35. PMID 39223928 — case report; authors attribute the injury to Agaricus blazei, not lion’s mane.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Lion’s Mane. National Institute of Diabetes and Digestive and Kidney Diseases; updated 5 January 2024. Bookshelf NBK599740 — NIH monograph; Likelihood Score E.
- European Commission. Novel Food Catalogue: Hericium erinaceus (Bull.) Pers. Updated 6 March 2025. EU Novel Food Catalogue — regulatory status; fruiting body not novel, dehydrated mycelium novel.
- Health Canada, Natural and Non-prescription Health Products Directorate. Mushrooms monograph. 31 October 2025. NNHPD monograph (PDF) — regulatory monograph; dose ceilings and risk statements.
- Surendran G, Saye J, Binti Mohd Jalil S, et al. Acute effects of a standardised extract of Hericium erinaceus (lion’s mane mushroom) on cognition and mood in healthy younger adults. Front Nutr. 2025;12:1405796. PMID 40276537 — human crossover, n=18; primary outcomes null, two measures significantly worse than control.
- Černelič Bizjak M, Jenko Pražnikar Z, Kenig S, et al. Effect of erinacine A-enriched Hericium erinaceus supplementation on cognition: a randomized, double-blind, placebo-controlled pilot study. J Funct Foods. 2024;115:106120. doi:10.1016/j.jff.2024.106120 — human RCT, n=33, 8 weeks; unadjusted analysis null; source for the LDL and glucose findings.
- Doar E, Meyer KW, Bair ZJ, et al. Influences of substrate and tissue type on erinacine production and biosynthetic gene expression in Hericium erinaceus. Fungal Biol Biotechnol. 2025;12(1):4. PMID 40181478 — analytical; no detectable erinacines in fruiting-body tissue.
- Keerthana CS, Kumari R, Beura M, et al. Unveiling the glucan profile: a comparative study of lion’s mane and shiitake mushrooms. Nat Prod Res. 2026;40(9):2627–30. PMID 40407020 — analytical; 17.44% beta-glucan, 0.673% alpha-glucan.
- Tang Y, Kahraman O, Goos AJ, Fields C. Simultaneous UHPLC-UV determination of hericenones, hericenes, erinacines and ergosterol in Hericium erinaceus raw materials or products. Molecules. 2026;31(3):569. PMID 41683546 — analytical; hundredfold hericenone variation across retail products. Authors employed by an ingredient supplier.
- Tsai PC, Wu YK, Hu JH, et al. Preclinical bioavailability, tissue distribution, and protein binding studies of erinacine A. Molecules. 2021;26(15):4510. PMID 34361662 — rats; blood-brain barrier penetration at 50 mg/kg.
- Muhanna M, Lund I, Bromberg M, et al. ALSUntangled #73: lion’s mane. Amyotroph Lateral Scler Frontotemporal Degener. 2024;25(3–4):420–3. PMID 38141002 — independent structured review by a neurologist panel.
- Chan YC, Lin TC, Chen CC, et al. Effects of erinacine A-enriched Hericium erinaceus on elderly hearing-impaired patients: a double-blind, randomized, placebo-controlled clinical trial. J Funct Foods. 2022;97:105220. doi:10.1016/j.jff.2022.105220 — human RCT, n=80; the only human trial to measure NGF. Not PubMed-indexed; sponsor-affiliated authors.
- Cornford N, Charnley M. Hericium erinaceus: a possible future therapeutic treatment for the prevention and delayed progression of Alzheimer’s disease? A narrative review. Nutr Res Rev. 2025;38(2):613–27. PMID 39988819 — narrative review; argues hericenones neither raise NGF in 1321N1 cells nor cross the blood-brain barrier.
Keep reading
About the author
Jimmy Daoutis
Founder, Advanced MycoTech
Jimmy founded Advanced MycoTech to bring evidence-based clarity to the confusing world of functional mushroom supplements. He reads the papers behind every claim on this site, publishes the corrections when he gets one wrong, and is upfront that he is not a doctor. Always consult your healthcare provider before starting any supplement.
Medical disclaimer: this article is for informational purposes only and does not constitute medical advice. Lion’s mane may interact with anticoagulant and antidiabetic medication, and anyone with a mushroom or mold allergy should avoid it — consult a qualified healthcare provider before taking it, particularly if you are pregnant, breastfeeding, taking prescription medication, or scheduled for surgery. Some links on this page are affiliate links; if you buy through them we may earn a small commission at no extra cost to you, and it never influences our recommendations or our evidence grading. Full disclosure.